Brokerages Set Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Price Target at $71.40

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) has been assigned an average recommendation of “Buy” from the eight analysts that are currently covering the firm, Marketbeat reports. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $71.40.

ARCT has been the subject of a number of recent analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arcturus Therapeutics in a research report on Monday, September 9th. Leerink Partnrs upgraded Arcturus Therapeutics to a “strong-buy” rating in a research note on Monday, August 12th. HC Wainwright restated a “buy” rating and issued a $63.00 price objective on shares of Arcturus Therapeutics in a research note on Friday, November 8th. Finally, Leerink Partners assumed coverage on Arcturus Therapeutics in a research report on Monday, August 12th. They set an “outperform” rating and a $70.00 target price for the company.

Insider Buying and Selling

In other news, COO Pad Chivukula sold 12,000 shares of the company’s stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $20.76, for a total transaction of $249,120.00. Following the transaction, the chief operating officer now owns 435,334 shares of the company’s stock, valued at $9,037,533.84. This represents a 2.68 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 15.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Arcturus Therapeutics

Several institutional investors have recently modified their holdings of the business. Russell Investments Group Ltd. bought a new position in shares of Arcturus Therapeutics in the 1st quarter worth $40,000. nVerses Capital LLC bought a new stake in shares of Arcturus Therapeutics in the third quarter worth about $42,000. Quest Partners LLC raised its holdings in Arcturus Therapeutics by 3,283.5% during the 2nd quarter. Quest Partners LLC now owns 3,688 shares of the biotechnology company’s stock worth $90,000 after buying an additional 3,579 shares during the period. CANADA LIFE ASSURANCE Co increased its position in shares of Arcturus Therapeutics by 10.5% during the first quarter. CANADA LIFE ASSURANCE Co now owns 4,492 shares of the biotechnology company’s stock worth $152,000 after acquiring an additional 428 shares in the last quarter. Finally, Public Employees Retirement System of Ohio raised its stake in shares of Arcturus Therapeutics by 63.8% in the 1st quarter. Public Employees Retirement System of Ohio now owns 4,620 shares of the biotechnology company’s stock valued at $156,000 after purchasing an additional 1,800 shares during the period. Institutional investors and hedge funds own 94.54% of the company’s stock.

Arcturus Therapeutics Stock Up 1.6 %

ARCT stock opened at $18.64 on Friday. The company has a market cap of $504.96 million, a price-to-earnings ratio of -8.40 and a beta of 2.64. Arcturus Therapeutics has a 12-month low of $14.93 and a 12-month high of $45.00. The company has a 50 day moving average of $19.86 and a two-hundred day moving average of $23.11.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.70) by $0.44. The firm had revenue of $41.67 million for the quarter, compared to analyst estimates of $49.16 million. Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. During the same quarter last year, the firm earned ($0.61) earnings per share. On average, research analysts anticipate that Arcturus Therapeutics will post -2.31 EPS for the current year.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.